Phosphoproteomics unveils the mode of action of clinical ATR inhibitors and explains their synergy with Gemcitabine in ...
Merck KGaA’s ATR inhibitor cancer drug has been cleared for further clinical trials after it showed encouraging activity in a phase 1 study. Short for ataxia telangiectasia and Rad3-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback